journal
MENU ▼
Read by QxMD icon Read
search

Oncology (Williston Park, NY)

journal
https://www.readbyqxmd.com/read/29940065/the-use-of-surgery-and-radiotherapy-as-treatment-of-regional-nodes-in-breast-cancer-patients
#1
REVIEW
Melissa P Mitchell, Priyanka Sharma
Ipsilateral regional nodal status is an important independent prognostic factor for patients with breast cancer. Several decisions regarding local therapy are necessary for patients found to have pathologically involved lymph node(s). This article reviews the role of completion dissection and/or radiation therapy in patients found to have positive sentinel lymph node(s), taking into consideration use of mastectomy vs lumpectomy, tumor characteristics, tumor biology, plans for systemic therapy, and patient preferences...
June 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29940064/immunotherapy-for-prostate-cancer-where-do-we-go-from-here-part-2-checkpoint-inhibitors-immunotherapy-combinations-tumor-microenvironment-modulation-and-cellular-therapies
#2
REVIEW
Amar Patel, Lawrence Fong
Therapeutic approaches that harness the power of the immune system to eliminate cancer cells have produced a paradigm shift in the management of a variety of malignancies. Prostate cancer has been a particularly active area of investigation in cancer immunotherapy, with significant laboratory and clinical evidence suggesting that this disease can be a viable target for cytotoxic immune cells. In the first article of this series, we discussed the diverse vaccination approaches that have been employed to prime native antigen-specific responses against prostate cancer, highlighting successes such as sipuleucel-T, as well as the significant challenges that remain...
June 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29940063/understanding-the-benefits-of-acupuncture-treatment-for-cancer-pain-management
#3
REVIEW
Gary Deng, Ting Bao, Jun J Mao
This article summarizes the current evidence regarding the use of acupuncture for pain management in cancer patients. It includes a description of how acupuncture is thought to work and what the intervention entails, data on acupuncture for managing pain caused by cancer or by cancer treatment (radiation, chemotherapy, endocrine therapy), how acupuncture is practiced in the US medical system, discussion of safety issues, and practical tips on how to integrate acupuncture into cancer care.
June 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29940061/a-35-year-old-woman-with-a-change-in-her2-expression-following-neoadjuvant-chemotherapy-for-invasive-breast-cancer
#4
Ericson Stoen, Peter Kabos, Kelly C Borden, Regina J Brown, Virginia F Borges, Jennifer R Diamond
No abstract text is available yet for this article.
June 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29940060/counterpoint-does-chemoimmunotherapy-still-have-a-role-in-cll
#5
Jennifer A Woyach
No abstract text is available yet for this article.
June 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29940059/point-does-chemoimmunotherapy-still-have-a-role-in-cll
#6
Philip A Thompson, Constantine S Tam
No abstract text is available yet for this article.
June 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29940058/how-lgl-t-cell-leukemia-at-19-gave-me-empathy-for-my-patients-and-my-colleagues
#7
Trevor J Bayliss
No abstract text is available yet for this article.
June 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29940057/newly-diagnosed-lung-cancer-which-molecular-tests-are-needed-for-optimal-treatment-decision-making
#8
Apar Kishor Ganti
The management of advanced non-small-cell lung cancer (NSCLC) has changed dramatically over the past few years due to our expanded knowledge of the molecular basis of lung cancer (driver mutations and immune targets) and drugs that affect these pathways, namely targeted agents and checkpoint inhibitors. Consequently, it is important to test patients with newly diagnosed advanced NSCLC for potentially significant molecular abnormalities prior to the initiation of treatment. This requires close coordination between the surgical pathologist, the molecular pathologist, and the medical oncologist to ensure that the biopsy specimen is used judiciously to get all necessary information...
June 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29940056/debra-patt-on-how-the-management-of-cancer-is-changing-as-patients-live-longer
#9
Debra Patt
No abstract text is available yet for this article.
June 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29940062/how-to-decide-which-dlbcl-patients-should-receive-cns-prophylaxis
#10
REVIEW
Kevin H Hall, Elyse Hall Panjic, Kelly Valla, Christopher R Flowers, Jonathon B Cohen
Secondary central nervous system (CNS) relapse in aggressive non-Hodgkin lymphoma (NHL) is a dismal diagnosis with poor outcomes. While prophylaxis against secondary CNS disease is recommended in patients with highly aggressive NHLs, such as Burkitt lymphoma, patients with diffuse large B-cell lymphoma (DLBCL) present a challenging clinical dilemma due to an inherently lower risk of CNS relapse. Current guidelines suggest that prophylaxis may benefit DLBCL patients at high risk for CNS relapse; however, it has been difficult to define which patients are truly at high risk...
June 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29847858/initiation-of-adt-in-a-man-with-locally-advanced-prostate-cancer-and-multiple-cardiovascular-risk-factors
#11
Francisco J Castro-Alonso, Jennifer Dominguez-Pineda, Guillermo Rosales-Sotomayor, Thomas W Flaig, María T Bourlon
No abstract text is available yet for this article.
May 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29847857/immunizing-cancer-patients-which-patients-which-vaccines-when-to-give
#12
Monika K Shah, Mini Kamboj
Patients receiving treatment for cancer should be considered for age- and indication-appropriate vaccinations, and the responsibility for administration of these vaccines is shared between the oncologist and the primary care provider. Certain vaccine-preventable diseases have higher incidence rates among cancer patients and are associated with worse clinical outcomes. The Centers for Disease Control and Prevention and the Advisory Committee on Immunization Practices recommend certain vaccines for routine use in adults, including those with cancer...
May 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29847856/robert-chapkin-on-relationships-between-the-gut-microbiome-diet-and-colorectal-cancer
#13
Robert S Chapkin
No abstract text is available yet for this article.
May 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29847855/implications-of-mutation-profiling-in-myeloid-malignancies-part-2-myeloproliferative-neoplasms-and-other-myeloid-malignancies
#14
REVIEW
Kelsey Sokol, Douglas Tremblay, Sheena Bhalla, Raajit Rampal, John O Mascarenhas
Myeloid malignancies arise from the acquisition of somatic mutations among various genes implicated in essential functioning of hematopoietic stem cells and progenitor cells. In this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases. We also discuss the entity known as clonal hematopoiesis of indeterminate potential, awareness of which is a result of the increasing availability and improved quality of mutation profiling...
May 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29847854/improving-adherence-to-endocrine-therapy-in-women-with-hr-positive-breast-cancer
#15
Julia P Brockway, Charles L Shapiro
Aromatase inhibitors (AIs) are the standard treatment for postmenopausal women with hormone receptor-positive breast cancers. One of the most common side effects of AIs is joint pain; it is also the most frequently cited reason for nonadherence and discontinuation before completion of the prescribed treatment course. Nonadherence and, in particular, discontinuation, can lead to increased rates of breast cancer mortality. The prevalence of AI-induced arthralgias is about 50%, and there are several interventions, including switching to a different AI, that can increase adherence...
May 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29847853/combination-controversies-checkpoint-inhibition-alone-or-in-combination-for-the-treatment-of-melanoma
#16
REVIEW
Allison Betof Warner, Michael A Postow
The immune checkpoint inhibitors ipilimumab, nivolumab, and pembrolizumab have dramatically improved outcomes for patients with metastatic melanoma; however, not all patients benefit from monotherapy with these agents. To address this issue, complementary combinations of immunotherapy are increasingly being explored as a strategy to improve outcomes. However, combinatorial approaches come with heightened risk of toxicity. In this review, we highlight combinations for which there are prospective data from clinical trials...
May 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29847852/counterpoint-chemotherapy-vs-abiraterone-for-the-initial-management-of-metastatic-prostate-cancer
#17
Robert J Jones
No abstract text is available yet for this article.
May 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29847851/point-chemotherapy-vs-abiraterone-for-the-initial-management-of-metastatic-prostate-cancer
#18
Pedro Isaacsson Velho, Mario A Eisenberger
No abstract text is available yet for this article.
May 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29847850/cdk4-6-inhibitors-game-changers-in-the-management-of-hormone-receptor%C3%A2-positive-advanced-breast-cancer
#19
REVIEW
Mirat Shah, Maria Raquel Nunes, Vered Stearns
The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors palbociclib, ribociclib, and abemaciclib are rapidly transforming the care of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) advanced breast cancer. Current clinical questions include how to choose among these agents and how to sequence them with other therapies. Areas of active inquiry include identifying predictive biomarkers for CDK4/6 inhibitors, deciding whether to continue CDK4/6 inhibitors after disease progression, creating novel treatment combinations, and expanding use beyond HR+/HER2- advanced breast cancer...
May 15, 2018: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/29684235/implications-of-mutation-profiling-in-myeloid-malignancies-part-1-myelodysplastic-syndromes-and-acute-myeloid-leukemia
#20
REVIEW
Douglas Tremblay, Kelsey Sokol, Sheena Bhalla, Raajit Rampal, John O Mascarenhas
The advent of high-throughput gene sequencing has revolutionized our understanding of the genetic mutations that drive myeloid malignancies. While these mutations are of interest pathobiologically, they are increasingly being recognized as clinically meaningful in providing diagnostic, prognostic, and therapeutic information to guide patient care. In this first part of our two-part review, we introduce mutation profiling as a relevant clinical tool for hematologists treating patients with myeloid malignancies...
April 15, 2018: Oncology (Williston Park, NY)
journal
journal
29689
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"